Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
5,279.93
Feb 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 2,827.00 - 5,470.00
Open     -
Vol / Avg. 0.00/1.67M
Mkt cap 31.61B*
P/E 14.65
Div/yield 12.51*
EPS 3.60*
Shares 590.09M
Beta     -
Inst. own     -
*GBP
Apr 30, 2015
Q1 2015 Shire PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Mar 3, 2015
Shire PLC at Cowen Health Care Conference - 2:20PM GMT - Add to calendar
Feb 12, 2015
Full Year 2014 Shire PLC Earnings Call
Feb 12, 2015
Full Year 2014 Shire PLC Earnings Release
Jan 13, 2015
Shire PLC at JPMorgan Healthcare Conference (Q&A)
Jan 13, 2015
Shire PLC at JPMorgan Healthcare Conference
Jan 11, 2015
Shire PLC to Acquire NPS Pharma as Further Step in Building a Leading Biotech Inc Call
Dec 10, 2014
Shire PLC Research and Development Day
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 126.05% 54.47%
Operating margin 30.53% 28.20%
EBITD margin - 39.14%
Return on average assets 63.31% 29.88%
Return on average equity 104.78% 46.80%
Employees 5,338 -
CDP Score - 91 B

Address

Citywest Business Campus 5 Riverwalk, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc. Effective May 12, 2014, the Company acquired Lumena Pharmaceuticals Inc.

Officers and directors

F. Ornskov M.D. Chief Executive Officer, Director
Age: 56
Jeff Poulton Interim Chief Financial Officer
Age: 47
Tatjana May General Counsel, Company Secretary
Age: 47
Susan S Kilsby Non-Executive Chairman of the Board
Age: 55
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 66
Dominic Blakemore Non-Executive Director
Age: 44
William Burns Non-Executive Independent Director
Age: 66
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 50